RIPK1 and infection: THP-1 and RAW264.7 cells were pre-treated with ZVAD-FMK (40 μM), Nec-1s (50 μM), and GSK’872 (20 nM), the inhibitors for pan-caspases, RIPK1, and RIPK3, respectively, followed by infection with ZIKV.